BRIDGEBIO PHARMA, INC.

(BBIO)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Top Midday Decliners

12/27/2021 | 12:40pm EDT


© MT Newswires 2021
Stocks mentioned in the article
ChangeLast1st jan.
BRIDGEBIO PHARMA, INC. -8.45% 6.72 Delayed Quote.-56.00%
DJ INDUSTRIAL 0.15% 31928.62 Real-time Quote.-12.27%
NASDAQ 100 -2.20% 11769.84 Real-time Quote.-26.26%
NATUZZI S.P.A. -2.91% 10 Delayed Quote.-37.23%
S&P 500 -0.81% 3941.48 Real-time Quote.-16.63%
All news about BRIDGEBIO PHARMA, INC.
05/24Goldman Sachs Adjusts BridgeBio Pharma's Price Target to $19 from $24, Keeps Buy Rating
MT
05/23BridgeBio Pharma Affiliate Phoenix Tissue Repair Announces Positive Results from Phase ..
AQ
05/20BridgeBio Pharma Affiliate Phoenix Tissue Repair Announces Positive Results from Phase ..
GL
05/20BridgeBio Pharma, Inc. and Phoenix Tissue Repair, Inc Announce Positive Results from Ph..
CI
05/18BRIDGEBIO PHARMA, INC. : Entry into a Material Definitive Agreement, Creation of a Direct ..
AQ
05/18TRANSCRIPT : BridgeBio Pharma, Inc. Presents at Citi Biopharma VIRTUAL Co-Panel Day, May-1..
CI
05/18BridgeBio Transaction Reflects Healthy Market For FDA Priority Review Vouchers
AQ
05/17BridgeBio Pharma to Participate in May Investor Events
GL
05/17BridgeBio Pharma to Participate in May Investor Events
AQ
05/16BridgeBio Pharma Sells Rare Pediatric Disease Priority Review Voucher for $110 Million ..
AQ
More news
Analyst Recommendations on BRIDGEBIO PHARMA, INC.
More recommendations
Financials (USD)
Sales 2022 91,5 M - -
Net income 2022 -560 M - -
Net Debt 2022 1 121 M - -
P/E ratio 2022 -1,81x
Yield 2022 -
Capitalization 993 M 993 M -
EV / Sales 2022 23,1x
EV / Sales 2023 32,1x
Nbr of Employees 577
Free-Float 64,1%
Chart BRIDGEBIO PHARMA, INC.
Duration : Period :
BridgeBio Pharma, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BRIDGEBIO PHARMA, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 10
Last Close Price 6,72 $
Average target price 24,50 $
Spread / Average Target 265%
EPS Revisions
Managers and Directors
Neil Kumar Chief Executive Officer & Director
Brian C. Stephenson Chief Financial Officer & Secretary
Uma Sinha Chief Scientific Officer
Richard H. Scheller Director, Chairman-Research & Development
Christine E. Siu Chief Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
BRIDGEBIO PHARMA, INC.-56.00%1 084
JOHNSON & JOHNSON6.04%472 179
PFIZER, INC.-9.55%296 704
ROCHE HOLDING AG-14.40%273 052
ELI LILLY AND COMPANY10.77%272 388
ABBVIE INC.10.13%261 585